Published in Drug Law Weekly, May 8th, 2007
For the quarter ended March 31, 2007, the Company reported a net loss of $55.1 million, or $0.93 per share. This compares to a net loss of $70.5 million, or $1.57 per share, for the same quarter in 2006 and to a net loss of $68.1 million, or $1.18 per share, for the prior quarter ended December 31, 2006.
For the quarter ended March 31, 2007, the Company recorded $12.0 million of net product sales for sales of Ranexa(R) (ranolazine extended-release tablets), which represents an increase of 33 percent compared to the $9.0 million of net product...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.